Journal
CLINICAL NUCLEAR MEDICINE
Volume 41, Issue 1, Pages 83-85Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RLU.0000000000000995
Keywords
metastatic renal cell carcinoma; prostate-specific membrane antigen (PSMA); PET; CT
Funding
- NCI NIH HHS [P50 CA103175, CA134675, K01 CA184288, CA184288, P30 CA006973, R01 CA134675, CA103175, U01 CA183031, CA183031] Funding Source: Medline
- NIBIB NIH HHS [EB006351, T32 EB006351] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [U01CA183031, R01CA134675, P30CA006973, K01CA184288, P50CA103175] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [T32EB006351] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy. A 58-year-old man with known metastatic clear cell RCC was imaged with both F-18-FDG and F-18-DCFPyL PET/CT. F-18-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to F-18-FDG, F-18-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
